Katherine Giacoletti

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · British Journal of Cancer · 2006 · 808 citations · Full text

Medicine, Gynecology, Preventive Medicine +17

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

Darron R. Brown, Susanne K. Kjær, Kristján Sigurðsson et al. · The Journal of Infectious Diseases · 2009 · 627 citations · Full text

Medicine, Oncology, Pathology +17

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

Nubia Muñóz, Susanne K. Kjær, Kristján Sigurðsson et al. · JNCI Journal of the National Cancer Institute · 2010 · 564 citations · Full text

Medicine, Gynecology, Infectious Diseases +16

Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women

Stan L. Block, Terry Nolan, Carlos Sattler et al. · PEDIATRICS · 2006 · 485 citations

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

Sven‐Eric Olsson, Luisa L. Villa, Ronaldo Lúcio Rangel Costa et al. · Vaccine · 2007 · 456 citations

Life Sciences, Immunology, Infectious Diseases +16